Turning on the Light Switch: Development and Implementation of an Immunotherapy Program for a Community-Based Oncology Practice
Immunotherapy represents a new era in the treatment of cancer patients. Immunomodulating agents increase overall survival and induce highly durable tumor responses in a rapidly expanding patient population. In this dynamic and rapidly evolving landscape, there is significant need to educate nurses and patients on this therapeutic class and its associated toxicities.
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach used in the treatment of various hematologic malignancies. CAR T-cell therapy utilizes gene transfer to reprogram the patient’s own T-cells to recognize and target tumor-associated antigens. Although groundbreaking and incredibly efficacious, CAR T-cell therapy has serious side effects that require prompt identification and intervention.
Running the “CAR” Shop: Nursing’s Role in Establishing the Intake and Management Standards of Patients Enrolled in CAR T-Cell Clinical Trials
Chimeric antigen receptor (CAR) T-cell therapy is considered a living drug. The patient’s own T-cells are genetically engineered to express CARs that recognize tumor-associated antigens. CAR T-cell therapy has proved efficacious in various hematologic malignancies, and is promising in solid tumors.
Oncology Nurse Practice: Exemplars in Assuring Safety in Clinical Implementation of Treatment Innovations in Melanoma
The immunotherapeutic landscape is dynamic and rapidly evolving. Immunomodulating therapies have proved effective in enhancing overall patient survival and inducing highly durable tumor responses. In this exciting and rapidly progressing setting, there is significant need for biosafety procedures to prevent unacceptable exposures.
Utilizing Nursing Handoff Communication to Manage Immune-Related Adverse Events in an Outpatient Immunotherapy Clinic
Immunotherapy represents a groundbreaking advance in the care of cancer patients. It modulates the body’s immune system to promote tumor destruction, and is now considered the fourth pillar of cancer treatment. Immunotherapeutic agents are associated with higher rates of immune-related adverse events that require immediate identification and intervention to prevent treatment cessation or fatal consequences.
Immunotherapy represents a revolutionary advance in the care of cancer patients, and is now considered the fourth pillar of cancer treatment. Immunomodulating agents promote tumor destruction and enhance patient survival. They also result in a higher incidence of immune-related adverse events that require prompt recognition for effective management.
Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy.
Overcoming HER2/ER Crosstalk: Neratinib Alone or in Combination with Fulvestrant in ER-Positive, HER2-Mutant Metastatic Breast Cancer in the Phase 2 SUMMIT Trial
The open-label, international, multicenter, multinational, phase 2 SUMMIT trial explored the efficacy and safety of neratinib monotherapy in patients with HER2-mutant metastatic breast cancer (MBC), and neratinib in combination with fulvestrant in patients with estrogen receptor (ER)-positive and HER2-positive MBC.
Mechanism of Action of Neratinib: An Irreversible Pan-HER Inhibitor in Late-Stage Clinical Development
Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. Despite the efficacy of trastuzumab in the adjuvant setting, 1 in 4 patients experience disease recurrence. Neratinib is a potent, irreversible, pan-HER tyrosine kinase inhibitor that can combat mechanisms of disease escape and recurrence experienced with other HER2-targeted therapies.
Beth Faiman discusses the difficulty of keeping abreast of all the new multiple myeloma treatments and how she personally stays up to date on all of the information.
Page 4 of 43
Results 31 - 40 of 428
Results 31 - 40 of 428